|View printer-friendly version|
|Global Blood Therapeutics Announces Proposed Public Offering of Common Stock|
A registration statement on Form S-1 relating to the securities proposed to be sold in this offering has been filed with the
The offering is being made solely by means of a prospectus. A copy of the preliminary prospectus can be obtained from
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We intend these forward-looking statements, including statements regarding our anticipated public offering, future expectations, plans and prospects for us, and the timing of these events, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, along with those set forth in our Annual Report on Form 10-K for the fiscal year ended
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-blood-therapeutics-announces-proposed-public-offering-of-common-stock-300286942.html
Myesha Edwards (investors), Global Blood Therapeutics, 650-351-4730, email@example.com; or Julie Normart (media), BrewLife, 415-946-1087, firstname.lastname@example.org